Ashwani Verma
Stock Analyst at UBS
(3.45)
# 959
Out of 4,734 analysts
58
Total ratings
57.14%
Success rate
2.9%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVDL Avadel Pharmaceuticals | Maintains: Buy | $22 → $14 | $7.75 | +80.65% | 2 | Jan 13, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $142 → $162 | $143.26 | +13.08% | 5 | Jan 8, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $415 → $475 | $358.93 | +32.34% | 4 | Jan 8, 2025 | |
| ACLX Arcellx | Maintains: Buy | $106 → $114 | $66.48 | +71.48% | 2 | Dec 10, 2024 | |
| EXEL Exelixis | Initiates: Neutral | $30 | $36.20 | -17.13% | 1 | Sep 19, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $56 | $39.05 | +43.41% | 1 | Sep 10, 2024 | |
| TEVA Teva Pharmaceutical | Maintains: Buy | $24 → $26 | $21.92 | +18.61% | 6 | Sep 3, 2024 | |
| CHRS Coherus BioSciences | Downgrades: Neutral | $4 → $1.5 | $1.39 | +7.91% | 4 | Aug 16, 2024 | |
| BHVN Biohaven | Maintains: Buy | $55 → $54 | $37.59 | +43.66% | 3 | Aug 13, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Neutral | $83 → $79 | $126.20 | -37.40% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $23 | $17.57 | +30.90% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $107 → $105 | $91.94 | +14.21% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $117 → $113 | $121.18 | -6.75% | 5 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $30.75 | -8.94% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $76 → $81 | $32.66 | +148.01% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $25 | $29.47 | -15.17% | 2 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $61 → $92 | $45.74 | +101.14% | 4 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $98.29 | -92.88% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $11.30 | +6.19% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.31 | +1,045.04% | 1 | Oct 11, 2022 |
Avadel Pharmaceuticals
Jan 13, 2025
Maintains: Buy
Price Target: $22 → $14
Current: $7.75
Upside: +80.65%
Neurocrine Biosciences
Jan 8, 2025
Maintains: Buy
Price Target: $142 → $162
Current: $143.26
Upside: +13.08%
United Therapeutics
Jan 8, 2025
Maintains: Buy
Price Target: $415 → $475
Current: $358.93
Upside: +32.34%
Arcellx
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $66.48
Upside: +71.48%
Exelixis
Sep 19, 2024
Initiates: Neutral
Price Target: $30
Current: $36.20
Upside: -17.13%
Harmony Biosciences Holdings
Sep 10, 2024
Initiates: Buy
Price Target: $56
Current: $39.05
Upside: +43.41%
Teva Pharmaceutical
Sep 3, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $21.92
Upside: +18.61%
Coherus BioSciences
Aug 16, 2024
Downgrades: Neutral
Price Target: $4 → $1.5
Current: $1.39
Upside: +7.91%
Biohaven
Aug 13, 2024
Maintains: Buy
Price Target: $55 → $54
Current: $37.59
Upside: +43.66%
Intra-Cellular Therapies
Aug 8, 2024
Maintains: Neutral
Price Target: $83 → $79
Current: $126.20
Upside: -37.40%
Aug 8, 2024
Maintains: Buy
Price Target: $25 → $23
Current: $17.57
Upside: +30.90%
Aug 6, 2024
Maintains: Buy
Price Target: $107 → $105
Current: $91.94
Upside: +14.21%
Jul 2, 2024
Maintains: Neutral
Price Target: $117 → $113
Current: $121.18
Upside: -6.75%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $30.75
Upside: -8.94%
Mar 18, 2024
Maintains: Buy
Price Target: $76 → $81
Current: $32.66
Upside: +148.01%
Feb 20, 2024
Downgrades: Sell
Price Target: $25
Current: $29.47
Upside: -15.17%
Jan 24, 2024
Downgrades: Neutral
Price Target: $61 → $92
Current: $45.74
Upside: +101.14%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $98.29
Upside: -92.88%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $11.30
Upside: +6.19%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $1.31
Upside: +1,045.04%